NCT04950400

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib For First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC)

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Beijing Chest Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the safety and efficacy of camrelizumab combined with chemotherapy in the first-line treatment of advanced in NSCLC patients.

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Carrelizumab + chemotherapy + apatinib	Subjects will receive 200 mg of karizumab every three weeks，Pemetrexed 500 mg / m2 was given on the first day of each cycle,Every three weeks was a period of administration,Carboplatin AUC 5 was given on the first day of each cycle and every three weeks was a cycle，Paclitaxel 175 mg / m2 was given on the first day of each cycle, and every three weeks was an administration cycle，with intravenous drip，Apatinib, 250 mg, oral, once a day (PO, QD), every 3 weeks as a cycle.

Timeline

• Start date: 2021-07-07
• Primary completion: 2023-12-12
• Completion: 2024-04-04
• First posted: 2021-07-06
• Last updated: 2021-07-06